Moleculin Biotech is trading at $8.50, up 7.59%, after its October 30 announcement that dosing was complete for all 90 Part A patients.
- MIRACLE is a pivotal Phase 2/3 trial evaluating Annamycin plus cytarabine for relapsed or refractory AML.
- Comprehensive Part A data are expected in Q1 2027 to help guide dose selection for Part B. The milestone was consistent with the reported premarket reaction; the supplied price context is the source for the current move.